These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33226181)

  • 1. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation.
    Iulita MF; Ower A; Barone C; Pentz R; Gubert P; Romano C; Cantarella RA; Elia F; Buono S; Recupero M; Romano C; Castellano S; Bosco P; Di Nuovo S; Drago F; Caraci F; Cuello AC
    Alzheimers Dement; 2016 Nov; 12(11):1132-1148. PubMed ID: 27452424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth factor metabolic dysfunction in Down's syndrome brains.
    Iulita MF; Do Carmo S; Ower AK; Fortress AM; Flores Aguilar L; Hanna M; Wisniewski T; Granholm AC; Buhusi M; Busciglio J; Cuello AC
    Brain; 2014 Mar; 137(Pt 3):860-72. PubMed ID: 24519975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease.
    Pentz R; Iulita MF; Ducatenzeiler A; Bennett DA; Cuello AC
    Mol Psychiatry; 2021 Oct; 26(10):6023-6037. PubMed ID: 32488129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology.
    Pentz R; Iulita MF; Mikutra-Cencora M; Ducatenzeiler A; Bennett DA; Cuello AC
    Neurobiol Dis; 2021 Jan; 148():105150. PubMed ID: 33130223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology.
    Cuello AC
    Adv Exp Med Biol; 2021; 1331():119-144. PubMed ID: 34453296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies.
    Nielsen HM; Minthon L; Londos E; Blennow K; Miranda E; Perez J; Crowther DC; Lomas DA; Janciauskiene SM
    Neurology; 2007 Oct; 69(16):1569-79. PubMed ID: 17761554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid.
    Hanzel CE; Iulita MF; Eyjolfsdottir H; Hjorth E; Schultzberg M; Eriksdotter M; Cuello AC
    J Alzheimers Dis; 2014; 40(3):667-78. PubMed ID: 24531161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome.
    Iulita MF; Cuello AC
    Trends Pharmacol Sci; 2014 Jul; 35(7):338-48. PubMed ID: 24962069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease.
    Counts SE; He B; Prout JG; Michalski B; Farotti L; Fahnestock M; Mufson EJ
    Curr Alzheimer Res; 2016; 13(7):800-8. PubMed ID: 26825093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases.
    Barba L; Bellomo G; Oeckl P; Chiasserini D; Gaetani L; Torrigiani EG; Paoletti FP; Steinacker P; Abu-Rumeileh S; Parnetti L; Otto M
    J Neurol Sci; 2024 Jul; 462():123059. PubMed ID: 38850771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.
    Karami A; Eyjolfsdottir H; Vijayaraghavan S; Lind G; Almqvist P; Kadir A; Linderoth B; Andreasen N; Blennow K; Wall A; Westman E; Ferreira D; Kristoffersen Wiberg M; Wahlund LO; Seiger Å; Nordberg A; Wahlberg L; Darreh-Shori T; Eriksdotter M
    Alzheimers Dement; 2015 Nov; 11(11):1316-28. PubMed ID: 25676388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease.
    Iulita MF; Bistué Millón MB; Pentz R; Aguilar LF; Do Carmo S; Allard S; Michalski B; Wilson EN; Ducatenzeiler A; Bruno MA; Fahnestock M; Cuello AC
    Neurobiol Dis; 2017 Dec; 108():307-323. PubMed ID: 28865749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease.
    Iulita MF; Cuello AC
    Curr Alzheimer Res; 2016; 13(1):53-67. PubMed ID: 26391047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome.
    Iulita MF; Caraci F; Cuello AC
    CNS Neurol Disord Drug Targets; 2016; 15(4):434-47. PubMed ID: 26996175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
    Wyganowska-Świątkowska M; Matthews-Kozanecka M; Matthews-Brzozowska T; Skrzypczak-Jankun E; Jankun J
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer's Disease and in Down Syndrome Dementia.
    Raha-Chowdhury R; Henderson JW; Raha AA; Vuono R; Bickerton A; Jones E; Fincham R; Allinson K; Holland A; Zaman SH
    J Alzheimers Dis; 2019; 69(1):91-109. PubMed ID: 30909239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.
    Do Carmo S; Kannel B; Cuello AC
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
    Portelius E; Soininen H; Andreasson U; Zetterberg H; Persson R; Karlsson G; Blennow K; Herukka SK; Mattsson N
    Neurodegener Dis; 2014; 14(2):98-106. PubMed ID: 24992945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.